Equities

Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.156
  • Today's Change0.003 / 1.89%
  • Shares traded55.93k
  • 1 Year change-83.32%
  • Beta1.3097
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

  • Revenue in USD (TTM)12.31m
  • Net income in USD-5.08m
  • Incorporated2006
  • Employees9.00
  • Location
    Sonoma Pharmaceuticals Inc5445 CONESTOGA COURT, SUITE 150BOULDER 80301United StatesUSA
  • Phone+1 (617) 243-0050
  • Fax+1 (707) 283-0551
  • Websitehttps://sonomapharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galmed Pharmaceuticals Ltd0.00-6.91m2.33m3.00--0.1408-----3.68-3.680.002.750.00----0.00-41.65-45.06-50.55-50.79------------0.00------61.31------
CNS Pharmaceuticals Inc0.00-18.85m2.35m3.00---------5.76-5.760.00-0.71320.00----0.00-255.54-132.47-1,018.78-185.75---------------------23.42------
PaxMedica Inc0.00-18.29m2.37m6.00--0.6931-----15.85-15.850.000.45740.00----0.00-463.93-755.77-915.89-------------1,760.660.00-------23.56------
Salarius Pharmaceuticals Inc0.00-12.54m2.39m2.00--0.3732-----4.54-4.540.001.340.00----0.00-118.12-69.27-160.07-79.89-------675.70----0.0519------60.32------
Resonate Blends Inc16.47k-1.42m2.41m6.00------146.58-0.0178-0.01780.0002-0.02470.0237-------203.52-680.29-----593.02-78.88-8,597.33-12,895.26---0.46917.89---66.73-56.57-316.63------
60 Degrees Pharmaceuticals Inc253.57k-3.99m2.43m3.00------9.58-0.6657-0.66570.04560.83820.05590.96381.8384,523.34-84.00-------87.15---1,504.04--2.39-1.890.0321---50.40--35.51------
Sonoma Pharmaceuticals Inc12.31m-5.08m2.43m9.00--0.319--0.1978-0.9608-0.96081.950.4890.86252.584.761,367,778.00-35.56-37.52-47.14-51.3539.1740.17-41.23-37.123.11--0.0065--5.10-4.44-1.28--7.54--
Agile Therapeutics Inc19.59m-14.47m2.51m19.00------0.128-9.84-9.849.11-5.511.604.415.791,031,158.00-118.12-94.24---142.6254.18---73.85-513.500.3269------80.02--43.08------
Windtree Therapeutics Inc0.00-20.29m2.52m15.00--8.74-----8.21-8.210.000.56550.00----0.00-57.68-44.51-63.50-48.38-------94,533.34----0.8179------48.25------
Qrons Inc0.00-789.36k2.53m2.00---------0.0581-0.05810.00-0.1090.00----0.00-45,235.53-1,513.45---------------5.76---------7.61------
American Green Inc-100.00bn-100.00bn2.57m6.00------------------------------------------------------------
DSwiss Inc1.47m-49.54k2.59m11.00--45.84157.511.76-0.0002-0.00020.00710.00033.92154.8254.81133,643.60-13.22-8.69-50.26-45.4724.4425.55-3.37-2.471.05-15.740.3961---20.5046.20-688.36---66.17--
Virpax Pharmaceuticals Inc0.00-15.19m2.62m7.00--1.36-----12.97-12.970.001.650.00----0.00-103.68-87.52-164.09-116.56------------0.00------29.84------
cbdMD Inc23.45m-23.98m2.62m52.00--0.9759--0.112-20.34-20.3412.190.88390.92272.0623.44450,876.20-78.62-38.59-101.68-41.5063.8463.80-85.21-87.980.6383-9.920.00---31.77120.9163.64---4.95--
Data as of May 03 2024. Currency figures normalised to Sonoma Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

1.93%Per cent of shares held by top holders
HolderShares% Held
Citadel Securities LLCas of 31 Dec 2023116.78k0.75%
Geode Capital Management LLCas of 31 Dec 202335.78k0.23%
JPMorgan Securities LLC (Investment Management)as of 31 Dec 202333.05k0.21%
Millennium Management LLCas of 31 Dec 202331.90k0.20%
HRT Financial LLCas of 31 Dec 202327.86k0.18%
SSgA Funds Management, Inc.as of 31 Dec 202324.32k0.16%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 202310.11k0.07%
Tower Research Capital LLCas of 31 Dec 20239.52k0.06%
UBS Securities LLCas of 31 Dec 20238.94k0.06%
Advisory Services Network LLCas of 31 Dec 20232.46k0.02%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.